Cargando…
Tremelimumab: research and clinical development
The immune checkpoint therapy is a relatively recent strategy that aims to tweak the immune system to effectively attack cancer cells. The understanding of the immune responses and their regulation at the intracellular level and the development of fully humanized monoclonal antibodies are the pillar...
Autores principales: | Comin-Anduix, Begoña, Escuin-Ordinas, Helena, Ibarrondo, Francisco Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809326/ https://www.ncbi.nlm.nih.gov/pubmed/27042127 http://dx.doi.org/10.2147/OTT.S65802 |
Ejemplares similares
-
Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013) -
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010) -
PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013) -
Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018) -
Tremelimumab
Publicado: (2012)